AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name:	Sunosi	Page:	1 of 3
Effective Date:	6/26/2024	Last Review Date:	6/5/2024

Applies to:	☐Illinois	☐Florida	☐Michigan
	☒New Jersey	☐Maryland	☒Florida Kids
	☒Pennsylvania Kids	☐Virginia	☐Texas

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Sunosi under the patient's prescription drug benefit.

Description:

Sunosi is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).

Limitations of use
Sunosi is not indicated to treat the underlying airway obstruction in OSA. Ensure that the underlying airway obstruction is treated (e.g., with continuous positive airway pressure (CPAP)) for at least one month prior to initiating Sunosi for excessive daytime sleepiness. Modalities to treat the underlying airway obstruction should be continued during treatment with Sunosi. Sunosi is not a substitute for these modalities.

Applicable Drug List:

Sunosi

Policy/Guideline:

The requested drug will be covered with prior authorization when the following criteria are met:

- The patient has excessive daytime sleepiness associated with narcolepsy
  AND
  - The request is for continuation of therapy
  AND
  - The patient experienced a decrease in daytime sleepiness with narcolepsy
  OR
  - The requested drug is being prescribed by, or in consultation with, a sleep specialist
  AND
  - The diagnosis has been confirmed by sleep lab evaluation
  AND
  - The patient has experienced an inadequate treatment response to armodafinil
    OR
  - The patient has experienced an intolerance to armodafinil
    OR
  - The patient has a contraindication that would prohibit a trial of armodafinil

OR

- The patient has excessive daytime sleepiness associated with obstructive sleep apnea (OSA)

  AND
  - The request is for continuation of therapy

  AND
  - The patient has experienced a decrease in daytime sleepiness with obstructive sleep apnea (OSA)

  AND
  - The patient is compliant with using continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP)

  OR
  - The requested drug is being prescribed by, or in consultation with, a sleep specialist

  AND
  - The diagnosis has been confirmed by polysomnography

  AND
  - The patient has been receiving treatment for the underlying airway obstruction (continuous positive airway pressure [CPAP] or bilevel positive airway pressure [BIPAP]) for at least one month

  AND
  - Treatment with continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) will continue

AND
- The patient has experienced an inadequate treatment response to armodafinil

OR
- The patient has experienced an intolerance to armodafinil

OR
- The patient has a contraindication that would prohibit a trial of armodafinil

Approval Duration and Quantity Restrictions:

Approval: 12 months

Quantity Level Limit: 30 tablets per 30 days

References:

1. Sunosi [package insert]. New York, NY: Axsome Therapeutics, Inc.; June 2022.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2023. https://online.lexi.com. Accessed December 4, 2023.
3. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 12/04/2023).

4. Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. *J Clin Sleep Med.* 2017;13(3):479-504.
5. Epstein LJ, Kristo D, Strollo PJ, et al. Clinical Guideline for the Evaluation, Management and Long-term Care of Obstructive Sleep Apnea in Adults. *J Clin Sleep Med*. 2009:5(3):263-276.
6. American Academy of Sleep Medicine. International Classification of Sleep Disorders, 3rd edition, text revision. American Academy of Sleep Medicine, 2023.
7. Sateia MJ. International Classification of Sleep Disorders- Third Edition: Highlights and Modifications. *CHEST*. 2014;146(5):1387-1394.
8. Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. *J Clin Sleep Med*. 2021;17(9):1881-1893.
9. Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. *J Clin Sleep Med.* 2021;17(9):1895-1945.